{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T15:22:31Z","timestamp":1780068151597,"version":"3.54.0"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2019,2,14]],"date-time":"2019-02-14T00:00:00Z","timestamp":1550102400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Delcath Systems Inc."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Intervent Radiol"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1007\/s00270-019-02177-x","type":"journal-article","created":{"date-parts":[[2019,2,14]],"date-time":"2019-02-14T12:38:07Z","timestamp":1550147887000},"page":"841-852","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["Safety of Percutaneous Hepatic Perfusion with Melphalan in Patients with Unresectable Liver Metastases from Ocular Melanoma Using the Delcath Systems\u2019 Second-Generation Hemofiltration System: A Prospective Non-randomized Phase II Trial"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2257-3232","authenticated-orcid":false,"given":"T. Susanna","family":"Meijer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark C.","family":"Burgmans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Fiocco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lioe-Fee","family":"de Geus-Oei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen","family":"Kapiteijn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora M.","family":"de Leede","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian H.","family":"Martini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rutger W.","family":"van der Meer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fred G. J.","family":"Tijl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander L.","family":"Vahrmeijer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,2,14]]},"reference":[{"key":"2177_CR1","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1245\/s10434-015-4968-3","volume":"23","author":"MS Hughes","year":"2016","unstructured":"Hughes MS, Zager J, Faries M, Alexander HR, Royal RE, Wood B, et al. Results of a randomized controlled multicenter phase III trial of percutaneous hepatic perfusion compared with best available care for patients with melanoma liver metastases. Ann Surg Oncol. 2016;23:1309\u201319.","journal-title":"Ann Surg Oncol"},{"key":"2177_CR2","unstructured":"The Dutch uveal melanoma guideline. 2017. \n                    http:\/\/www.oncoline.nl\/uploaded\/docs\/AlgemeenOncolineEnPallialine\/2017_06_26_Nederlandse_vertaling_definitieve_aanbevelingen_richtlijn_uveamelanoom.pdf\n                    \n                  . Accessed 14 Jan 2018."},{"key":"2177_CR3","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1159\/000367715","volume":"1","author":"PL Triozzi","year":"2015","unstructured":"Triozzi PL, Singh AD. Adjuvant therapy of uveal melanoma: current status. Ocul Oncol Pathol. 2015;1:54\u201362.","journal-title":"Ocul Oncol Pathol"},{"key":"2177_CR4","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1007\/s00270-015-1276-z","volume":"39","author":"MC Burgmans","year":"2016","unstructured":"Burgmans MC, de Leede EM, Martini CH, Kapiteijn E, Vahrmeijer AL, van Erkel AR. Percutaneous isolated hepatic perfusion for the treatment of unresectable liver malignancies. Cardiovasc Intervent Radiol. 2016;39:801\u201314.","journal-title":"Cardiovasc Intervent Radiol"},{"key":"2177_CR5","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1055\/s-0034-1366081","volume":"186","author":"TJ Vogl","year":"2014","unstructured":"Vogl TJ, Zangos S, Scholtz JE, Schmitt F, Paetzold S, Trojan J, et al. Chemosaturation with percutaneous hepatic perfusions of melphalan for hepatic metastases: experience from two European centers. Fortschr R\u00f6ntgenstr. 2014;186:937\u201344.","journal-title":"Fortschr R\u00f6ntgenstr"},{"issue":"5","key":"2177_CR6","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1002\/jso.23501","volume":"109","author":"MR Forster","year":"2014","unstructured":"Forster MR, Rashid OM, Perez MC, Choi J, Chaudhry T, Zager JS. Chemosaturation with percutaneous hepatic perfusion for unresectable metastatic melanoma or sarcoma to the liver: a single institution experience. J Surg Oncol. 2014;109(5):434\u20139.","journal-title":"J Surg Oncol"},{"issue":"3","key":"2177_CR7","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1245\/s10434-007-9781-1","volume":"15","author":"N Miao","year":"2008","unstructured":"Miao N, Pingpank JF, Alexander HR, Steinberg SM, Beresneva T, Quezado ZM. Percutaneous hepatic perfusion in patients with metastatic liver cancer: anesthetic, hemodynamic, and metabolic considerations. Ann Surg Oncol. 2008;15(3):815\u201323.","journal-title":"Ann Surg Oncol"},{"issue":"15","key":"2177_CR8","doi-asserted-by":"publisher","first-page":"3465","DOI":"10.1200\/JCO.2005.00.927","volume":"23","author":"JF Pingpank","year":"2005","unstructured":"Pingpank JF, Libutti SK, Chang R, Wood BJ, Neeman Z, Kam AW, et al. Phase I study of hepatic arterial melphalan infusion and hepatic venous hemofiltration using percutaneously placed catheters in patients with unresectable hepatic malignancies. J Clin Oncol. 2005;23(15):3465\u201374.","journal-title":"J Clin Oncol"},{"issue":"3","key":"2177_CR9","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1001\/archsurg.138.3.325","volume":"138","author":"E Savier","year":"2003","unstructured":"Savier E, Azoulay D, Huguet E, Lokiec F, Gil-Delgado M, Bismuth H. Percutaneous isolated hepatic perfusion for chemotherapy: a phase 1 study. Arch Surg. 2003;138(3):325\u201332.","journal-title":"Arch Surg"},{"key":"2177_CR10","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1007\/s00432-017-2461-z","volume":"143","author":"MM Kirstein","year":"2017","unstructured":"Kirstein MM, Marquardt S, Jedicke N, Marhenke S, Koppert W, Manns MP, et al. Safety and efficacy of chemosaturation in patients with primary and secondary liver tumors. J Cancer Res Clin Oncol. 2017;143:2113\u201321.","journal-title":"J Cancer Res Clin Oncol"},{"key":"2177_CR11","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1002\/jso.24956","volume":"117","author":"I Karydis","year":"2018","unstructured":"Karydis I, Gangi A, Wheater MJ, Choi J, Wilson I, Thomas K, et al. Percutaneous hepatic perfusion with melphalan in uveal melanoma: a safe and effective treatment modality in an orphan disease. J Surg Oncol. 2018;117:1170\u20138.","journal-title":"J Surg Oncol"},{"key":"2177_CR12","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1007\/s00270-017-1588-2","volume":"40","author":"TJ Vogl","year":"2017","unstructured":"Vogl TJ, Koch SA, Lotz G, Gebauer B, Willinek W, Engelke C, et al. Percutaneous isolated hepatic perfusion as a treatment for isolated hepatic metastases of uveal melanoma: patient outcome and safety in a multi-centre study. Cardiovasc Intervent Radiol. 2017;40:864\u201372.","journal-title":"Cardiovasc Intervent Radiol"},{"key":"2177_CR13","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1007\/s00270-017-1630-4","volume":"40","author":"EM Leede De","year":"2017","unstructured":"De Leede EM, Burgmans MC, Meijer TS, Martini CH, Tijl FGJ, Vuyk J, et al. Prospective clinical and pharmacological evaluation of the Delcath system\u2019s second-generation (GEN2) hemofiltration system in patients undergoing percutaneous hepatic perfusion with melphalan. Cardiovasc Intervent Radiol. 2017;40:1196\u2013205.","journal-title":"Cardiovasc Intervent Radiol"},{"key":"2177_CR14","unstructured":"https:\/\/www.eortc.be\/services\/doc\/ctc\/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf\n                    \n                  . Accessed 1 July 2018"}],"container-title":["CardioVascular and Interventional Radiology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00270-019-02177-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00270-019-02177-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00270-019-02177-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,13]],"date-time":"2020-02-13T19:08:59Z","timestamp":1581620939000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00270-019-02177-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,14]]},"references-count":14,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["2177"],"URL":"https:\/\/doi.org\/10.1007\/s00270-019-02177-x","relation":{},"ISSN":["0174-1551","1432-086X"],"issn-type":[{"value":"0174-1551","type":"print"},{"value":"1432-086X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,14]]},"assertion":[{"value":"20 October 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declare that Delcath Systems Inc. had no involvement in any part of the study and that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Consent for publication was obtained for every individual person\u2019s data included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed Consent"}}]}}